TrialJournal for immunotherapy of cancer2025

Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) safely induces disease remissions in relapsed, refractory multiple myeloma.

Binod Dhakal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.